1.Occult Hepatitis B Virus Infection in Chronic Hepatitis C.
The Korean Journal of Gastroenterology 2013;62(3):154-159
Occult HBV infection is defined as the presence of HBV DNA in the liver (with or without detectable or undetectable HBV DNA in the serum) of individuals testing negative for HBsAg. Studies on occult HBV infection in hepatitis C patients have reported highly variable prevalence, because the prevalence of occult HBV infection varies depending on the hepatitis B risk factors and methodological approaches. The most reliable diagnostic approach for detecting occult HBV detection is through examination of liver DNA extracts. HCV has been suspected to strongly suppress HBV replication up to the point where it may be directly responsible for occult HBV infection development. However, more data are needed to arrive at a definitive conclusion regarding the role of HCV in inducing occult HBV infection. Occult HBV infection in chronic hepatitis C patients is a complex biological entity with possible relevant clinical implications. Influence of occult HBV infection on the clinical outcomes of chronic hepatitis C may be considered negative. However, recent studies have shown that occult HBV infection could be associated with the development of hepatocellular carcinoma and contribute to the worsening of the course of chronic liver disease over time in chronic hepatitis C patients. Nevertheless, the possible role of occult HBV infection in chronic hepatitis C is still unresolved and no firm conclusion has been made up until now. It still remains unclear how occult HBV infection affects the treatment of chronic hepatitis C. Therefore, in order to resolve current controversies and understand the pathogenic role and clinical impacts of occult HBV infection in chronic hepatitis C patients, well-designed clinical studies are needed.
Carcinoma, Hepatocellular/complications
;
DNA, Viral/analysis
;
Hepacivirus/genetics
;
Hepatitis B/*complications/*diagnosis/drug therapy
;
Hepatitis B virus/genetics
;
Hepatitis C, Chronic/*complications/*diagnosis/drug therapy
;
Humans
;
Interferon-alpha/therapeutic use
;
Liver/virology
;
Liver Neoplasms/complications
3.Effect of antiviral therapy on the prognosis of patients with chronic hepatitis B-related cirrhosis.
Guang-jun SONG ; Bo FENG ; Hui-ying RAO ; Jian WANG ; Lai WEI
Chinese Journal of Hepatology 2013;21(6):438-441
OBJECTIVETo conduct a meta-analysis to study the effect of antiviral therapy on the prognosis of patients with chronic hepatitis B (CHB)-related cirrhosis.
METHODSPubMed, EMBASE, the Cochrane Central Register of Controlled Trials, Chinese Biomedical Database, Chinese Journals Full-text Database, and Wan Fang Digital Journal Full-text Database were searched for studies on nucleoside analogues antiviral treatment outcome of patients with CHB-related cirrhosis (vs. controls without antiviral therapy) published between January 1998 and March 2012. Data extraction and quality assessment was performed by two independent investigators. Heterogeneity was assessed by the I2 index. In the case of homogeneity the random-effects model was applied, and in the case of heterogeneity the fixed-effects model was applied. The odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.
RESULTSSeven studies were included in the meta-analysis: one high-quality randomized-controlled trial (RCT) study, four prospective cohort studies, and two case-control studies. Compared to the control group, the group treated with antiviral therapy showed a significantly lower incidence of hepatocellular carcinoma (11.2%, 76/680 vs. 6.7%, 75/1116; OR = 0.56, 95% CI: 0.40 to 0.79, P = 0.001) and lower mortality (23.6%, 78/331 vs. 10.8%, 43/398; OR = 0.36, 95% CI: 0.23 to 0.55, P = 0.000).
CONCLUSIONAntiviral therapy with nucleoside analogues significantly reduces the incidence of hepatocellular carcinoma and mortality in patients with CHB-related cirrhosis.
Antiviral Agents ; therapeutic use ; Hepatitis B, Chronic ; complications ; diagnosis ; drug therapy ; Humans ; Liver Cirrhosis ; diagnosis ; drug therapy ; etiology ; Nucleotides ; therapeutic use ; Prognosis
4.A Case of Acute Disseminated Encephalomyelitis Associated with Hepatitis C Virus Infection.
Jae Eun SIM ; Jun Bum LEE ; Yu Na CHO ; Sang Hyun SUH ; Ja Kyung KIM ; Kyung Yul LEE
Yonsei Medical Journal 2012;53(4):856-858
Acute disseminated encephalomyelitis (ADEM) is a monophasic autoimmune demyelinating disease of the central nervous system, which typically follows acute viral or bacterial infection or vaccination. We report a case of ADEM associated with hepatitis C virus (HCV) infection with positive serum and cerebrospinal fluid (CSF) anti-HCV antibody. After steroid treatment, neurologic symptoms were improved. Virus triggers autoimmunity or direct viral invasion plays a part in the genesis of ADEM. This is the first reported case of ADEM with anti-HCV antibody in the CSF.
Encephalomyelitis, Acute Disseminated/*diagnosis/drug therapy/etiology/virology
;
Female
;
Hepacivirus/pathogenicity
;
Hepatitis C/*complications
;
Humans
;
Methylprednisolone/therapeutic use
;
Middle Aged
7.Synchronous Hepatocellular Carcinoma and B-Cell Non-Hodgkin's Lymphoma in Chronic Hepatitis C Patient.
Soon Il LEE ; Nae Yun HEO ; Seung Ha PARK ; Young Don JOO ; Il Hwan KIM ; Jeong Ik PARK ; Ji Yeon KIM ; Seung Ho KIM ; Hye Kyung SHIM
The Korean Journal of Gastroenterology 2014;64(3):168-172
Hepatitis C virus (HCV) is one of the main viral causes of hepatocellular carcinoma (HCC) and is associated with lymphoproliferative disorder such as non-Hodgkin's lymphoma (NHL). However, there are only few case reports on concomitantly induced NHL and HCC by HCV. Herein, we report a case of synchronous NHL and HCC in a patient with chronic hepatitis C which was unexpectedly diagnosed during liver transplantation surgery. This case suggests that although intrahepatic lymph node enlargements are often considered as reactive or metastatic lymphadenopathy in chronic hepatitis C patients with HCC, NHL should also be considered as a differential diagnosis.
Antineoplastic Agents/therapeutic use
;
Carcinoma, Hepatocellular/complications/*diagnosis/radiotherapy
;
Drug Therapy, Combination
;
Embolization, Therapeutic
;
Fluorodeoxyglucose F18
;
Gadolinium DTPA
;
Genotype
;
Hepatitis B virus/genetics
;
Hepatitis C, Chronic/complications/*diagnosis/*virology
;
Humans
;
Liver Neoplasms/complications/*diagnosis/radiotherapy
;
Lymph Nodes/pathology
;
Lymphoma, Non-Hodgkin/complications/*diagnosis/drug therapy
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Positron-Emission Tomography
;
Tomography, X-Ray Computed
9.Co-development of autoimmune hepatitis and Sjogren's syndrome triggered by the administration of herbal medicines.
Hyo Jeong OH ; Young Mi MOK ; Moon Seong BAEK ; Ji Kyeong LEE ; Bong Soo SEO ; Tae Hyeon KIM ; Keum Ha CHOI ; In Kyeom HWANG ; Ji Eun RA ; Yong Reol OH ; Yong Sung KIM ; Eun Young CHO ; Haak Cheoul KIM ; Young Woo SOHN
Clinical and Molecular Hepatology 2013;19(3):305-308
Autoimmune hepatitis (AIH) has been reported in association with Sjogren's syndrome (SS). Drug-induced AIH has been rarely reported. A rare case of the co-development of AIH and SS in a 53-year-old woman after the consumption of herbal medicines is described. After admission, the patient complained of dryness in her mouth, and she was subsequently diagnosed with SS, which had not been detected previously. The patient's bilirubin and aminotransferase levels initially decreased following conservative management; however, they later began to progressively increase. A diagnosis of AIH was made based on the scoring system proposed by the International Autoimmune Hepatitis Group. The patient was administered a combination of prednisolone and azathioprine, and the results of follow-up liver-function tests were found to be within the normal range. This is an unusual case of AIH and SS triggered simultaneously by the administration of herbal medicines.
Alanine Transaminase/blood
;
Aspartate Aminotransferases/blood
;
Azathioprine/therapeutic use
;
Bilirubin/blood
;
Female
;
Hepatitis, Autoimmune/complications/*diagnosis/drug therapy
;
*Herbal Medicine
;
Humans
;
Liver/pathology
;
Liver Function Tests
;
Middle Aged
;
Prednisolone/therapeutic use
;
Sjogren's Syndrome/complications/*diagnosis/drug therapy
10.Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes.
Yoonsang PARK ; Yuri CHO ; Eun Ju CHO ; Yoon Jun KIM
Clinical and Molecular Hepatology 2015;21(2):150-157
BACKGROUND/AIMS: Overlap syndrome of autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) (AIH-PBC overlap syndrome) is a rare disease that has not been clearly characterized in Korean patients. This study investigated the clinical features of AIH-PBC overlap syndrome compared with those of AIH and PBC alone. METHODS: This retrospective cohort study included 158 consecutive patients who were diagnosed as AIH (n=61), PBC (n=81), or AIH-PBC overlap syndrome (n=9) based on the Paris and the International Autoimmune Hepatitis Group (IAIHG) criteria from 2001 to 2011 in Korea. We compared the clinical features of these three groups retrospectively, including their biochemical characteristics, treatments, responses, and clinical outcomes. RESULTS: The AIH-PBC overlap syndrome patients exhibited biochemical characteristics of both AIH and PBC, and showed a similar response to ursodeoxycholic acid (UDCA) monotherapy as for the PBC patients. However, the response of AIH-PBC overlap syndrome patients to UDCA and steroid combination therapy was worse than the response of AIH patients to steroid-based therapy (P=0.024). Liver cirrhosis developed more rapidly in AIH-PBC overlap syndrome patients than in AIH patients group (P=0.013), but there was no difference between AIH-PBC overlap syndrome patients and PBC patients. The rates of developing hepatic decompensation did not differ significantly between the groups. CONCLUSIONS: The AIH-PBC overlap syndrome patients exhibited a worse response to UDCA and steroid combination therapy and a faster cirrhotic progression compared with AIH patients.
Adult
;
Aged
;
Cohort Studies
;
Drug Therapy, Combination
;
Female
;
Hepatitis, Autoimmune/complications/*diagnosis
;
Humans
;
Liver/metabolism/pathology
;
Liver Cirrhosis, Biliary/complications/*diagnosis/drug therapy
;
Male
;
Middle Aged
;
Republic of Korea
;
Retrospective Studies
;
Steroids/therapeutic use
;
Treatment Outcome
;
Ursodeoxycholic Acid/therapeutic use